Latest:
What Australia’s Experience Reveals About Biosimilar Adoption and Pricing
Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization amid tighter health care budgets.
© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Authors
Dinakaran Balasubramanian
Dinakaran is an accomplished commercial professional with rich experience of over 12 years in the pharmaceutical industry. He has an extensive understanding of the US commercial landscape and its key economic drivers, specifically in generic injectables and biosimilars. He is currently serving as the Head of Commercial Strategy & Insights for Biologics in North America for Dr Reddys Laboratories. His role extends to providing valuable insights into pricing considerations, competitive intelligence, and market dynamics, crucial for driving product adoption and profitability objectives. During his long tenure, he has handled multiple roles across Sales, strategy, pricing, and product management.
Latest:
The Underlying Economics of Unbranded Biologics
Unbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.
Travis Brewer
Travis Brewer serves as the vice president of payer and public health strategy at Texas Oncology.
Latest:
Enhancing Biosimilar Adoption in Value-Based Oncology Care
Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.
Advertisement
Advertisement